Logo

COEP

Coeptis Therapeutics, Inc.

COEP

Coeptis Therapeutics, Inc. • NASDAQ
$18.73 ▼ -0.37% (-0.07)
Market Cap $65.81 M
52w High $21.41
52w Low $2.31
Dividend Yield 0%
P/E -5.22
Volume 40.87K
Outstanding Shares 3.51M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $237.441K ▲ $2.669M ▼ $-159.36K ▲ -67.116% ▲ $-0.58 ▲ $-2.53M ▲
Q2-2025 $200.681K ▲ $4.677M ▲ $-3.535M ▼ -1.761K% ▲ $-0.95 ▲ $-3.961M ▼
Q1-2025 $62.874K ▲ $4.075M ▲ $-3.058M ▼ -4.863K% ▼ $-0.99 ▼ $-3.044M ▼
Q4-2024 $0 $1.902M ▲ $-3.012M ▼ 0% $4.09 ▲ $-2.673M ▼
Q3-2024 $0 $1.71M $-1.829M 0% $-0.046 $-1.5M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.33M ▲ $16.282M ▲ $3.265M ▼ $12.466M ▲
Q2-2025 $2.987M ▼ $12.191M ▼ $5.111M ▼ $6.096M ▼
Q1-2025 $4.268M ▲ $13.453M ▲ $5.99M ▲ $6.479M ▲
Q4-2024 $532.885K ▼ $8.909M ▼ $5.041M ▲ $3.185M ▼
Q3-2024 $1.137M $8.956M $3.974M $4.825M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.739M ▲ $-2.152M ▲ $0 $5.064M ▲ $2.912M ▲ $-2.152M ▲
Q2-2025 $-4.335M ▼ $-2.397M ▼ $0 $125.1K ▼ $-2.272M ▼ $-2.397M ▼
Q1-2025 $-3.421M ▼ $-2.366M ▼ $0 ▼ $6.102M ▲ $3.735M ▲ $-2.366M ▼
Q4-2024 $-3.012M ▼ $-1.437M ▲ $100K ▲ $731.971K ▼ $-604.568K ▼ $-1.437M ▲
Q3-2024 $-1.829M $-1.893M $0 $1.475M $-417.622K $-1.893M

Five-Year Company Overview

Income Statement

Income Statement Coeptis is a classic pre‑revenue biotech: it has essentially no product sales and only reports ongoing losses from research and corporate overhead. Those losses are not huge in absolute dollar terms, but with no revenue coming in, every dollar spent must be funded from cash on hand or new financing. Earnings per share have also swung around sharply over time, partly reflecting reverse stock splits and share structure changes rather than changes in the underlying business. Overall, the income statement shows an early‑stage R&D company that is still far from commercial scale.

Balance Sheet

Balance Sheet The balance sheet is extremely thin, with only a very small base of total assets and effectively no reported cash or debt. Shareholders’ equity hovers around break‑even and has been slightly negative at times, which signals financial fragility and a reliance on external capital. The absence of debt reduces immediate interest and repayment pressures, but it also reflects how small the company still is. Multiple reverse stock splits in recent years point to pressure on the share price and a history of equity restructuring, which often goes hand in hand with capital raises and dilution risk.

Cash Flow

Cash Flow Cash flow is negative from operations, consistent with a company spending on R&D and overhead without any product revenue. Free cash flow is also negative, but there is almost no spending on physical assets, so the cash burn is mainly people, trials, and corporate costs. Given the near‑zero reported cash balance, this pattern underlines a key risk: the business depends on future financing, partnerships, or non‑core income streams to keep funding its pipeline. There is no sign yet of the business generating its own cash to reinvest.

Competitive Edge

Competitive Edge Coeptis operates in one of the most competitive and high‑stakes areas of biotech: cell therapies for cancer. It faces much larger, better‑funded rivals that are also working on allogeneic and “off‑the‑shelf” cell therapies. The company’s edge is its differentiated technology concepts, such as modular targeting (SNAP‑CAR) and antibody‑resistant NK cells (GEAR‑NK), plus academic partnerships that provide scientific credibility. However, without clinical proof and strong balance sheet backing, its position is still more “promising idea” than established player. Execution, trial results, and the ability to secure partners will largely determine whether its niche can translate into a durable competitive position.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Coeptis. The SNAP‑CAR platform aims to create tunable, “universal” cell therapies that can be redirected to different cancer targets using antibody adaptors, potentially improving safety and flexibility versus traditional single‑target CAR‑T therapies. GEAR‑NK focuses on making NK cells resistant to certain antibodies so they can be more effective in combination treatments, particularly for blood cancers. These are creative solutions to real limitations of current cell therapies, but they are still at preclinical or very early‑stage status. The company is also experimenting with diversification via a technology division centered on AI‑driven marketing tools, which is unusual for a biotech and could either provide helpful side income or become a strategic distraction. Overall, the R&D story is high‑concept and high‑risk, with meaningful scientific upside if early data translate into human success.

Summary

Coeptis Therapeutics is an early‑stage, high‑risk biotechnology company with no revenue, a very small asset base, and ongoing cash burn typical of a pre‑commercial R&D platform. Its financials signal dependence on external funding and a history of share restructuring, which raises dilution and going‑concern questions. On the positive side, the scientific story is ambitious: proprietary SNAP‑CAR and GEAR‑NK platforms target genuine gaps in current cell therapy approaches, with academic backing and a focus on off‑the‑shelf treatments. Against that, the company operates in a crowded, capital‑intensive field dominated by larger competitors, and its key programs are still preclinical, meaning long timelines and significant uncertainty. In short, this is a science‑driven, early‑stage platform with intriguing technology but a very fragile financial foundation and substantial development and funding risk.

NEWS

September 23, 2025 · 8:00 AM UTC

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Read more